Glaxo Set To File Nucala In COPD, Despite Mixed Phase III Results
Executive Summary
An 'imperfect biomarker' – that's how a New England Journal of Medicine editorial describes the eosinophil count used in METREX and METREO studies.
You may also be interested in...
Dupixent Succeeds Where Other Biologic Drugs Failed – In COPD
Sanofi and Regeneron could be poised to add another blockbuster indication to the IL-4/IL-13 inhibitor, for chronic obstructive pulmonary disease.
US FDA Rejection Stings Nucala In COPD; New Study May Be Needed
Mepolizumab would be first drug for chronic obstructive pulmonary disorder to use eosinophil count as a biomarker, but FDA’s complete response letter says more clinical data are needed.
Did GSK's Nucala Trials In COPD Strengthen Confidence In The Eosinophil Biomarker?
US FDA was hoping Pulmonary-Allergy Drugs Advisory Committee could help provide some clarity on its use, but there still are many questions.